Chicago GYN Oncology Updates

This conference has been CANCELLED. 

Chicago GYN Oncology Updates is organized by Meeting Achievements and will be held on May 15, 2020 at Gleacher Center, Chicago, Illinois, United States of America.

Target Audience:
This activity is designed for gynecologic oncologists, medical oncologists, radiation oncologists, gynecologists, trainees, research scientists, nurses, nurse practitioners, physician assistants, and other healthcare professionals dedicated to the care of patients with gynecologic malignancies.

Accreditation:
Physician Credit:
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit:
This live activity is designated for a maximum of 3.5 continuing nursing education units.

American Board of Internal Medicine MOC Part II Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Course Description:
Chicago GYN Oncology Updates will provide access to the premier educational and scientific updates for women’s healthcare professionals from the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, including information and resources for members of the entire gynecologic cancer care team who provide treatment and care in the areas of chemotherapy, radiation therapy, and surgery. It will provide participants with advanced knowledge of the latest innovations in the evaluation and treatment of gynecologic cancers.

Learning Objectives:
At the conclusion of this activity, participants will be able to:
• Define the mechanisms of action and side effect profiles of new gynecologic cancer therapies.
• Discuss how to apply recent results regarding use of PARP inhibitors in front-line therapy of ovarian cancer.
• Identify strategies to explain the efficacy results of immunotherapy in endometrial cancer to patients.
• State how to implement new developments in surgical practice of gynecologic malignancies.
• Determine the sequencing and combination of new agents used for gynecologic cancer care with current therapies.
• Identify contextual barriers to the integration of new gynecologic cancer agents to improve patient outcomes.
• Describe how ongoing trials using adoptive immunotherapy in gynecologic malignancies can potentially be used to improve patient outcomes.